#next generation sequencing market share

[trendingreportz]

Next Generation Sequencing Market - Forecast(2024 - 2030)

The global Next Generation Sequencing market is estimated to grow at a CAGR of 17.25% during the forecast period 2019–2025. The market is projected to grow from $4,570Mn in 2018 to $13,714Mn by 2025. Next Generation Sequencing (NGS) is a mixture of techniques used in diagnosing and treating various diseases. Next-generation sequencing (NGS) is emerging as a valuable method for obtaining a deeper and more accurate look into the molecular underpinnings of individual tumors. 

Key Takeaways

In the coming years, growing interest in the Next Generation Sequencing by Healthcare industry and Medical technology firms is anticipated to drive development in the Next Generation Sequencing industry.

Key sustainability strategies such as mergers or acquisitions, product and service launch are being adopted by the market players to ensure the growth of Next Generation Sequencing market. 

Asia-pacific is estimated to record the fastest CAGR during the forecast period for New Generation Sequencing Market.

Request Sample

By Sequence Type - Segment Analysis

In 2018, Whole Genome Sequencing segment dominated the NGS market in terms of revenue. Its popularity can be attributed to the fact that it allows researchers to sequence genes and genomes, and allow them to look for mutations which cause diseases at a faster pace than traditional testing methods.

By Product Type - Segment Analysis

Services Segment is estimated to dominate the NGS Market in 2018 in terms of revenue. It accounted for a significant share in 2018. This market is projected to grow owing to the increasing use of NGS software and services for sequencing procedures in the healthcare field. 

End User - Segment Analysis

In End user segment, Clinical Diagnostic Laboratories featured to show the largest growth among others. This is attributed to substantial growth in the number of research and diagnostic laboratories all round the world. Hospitals and Healthcare Institutions are also an aiding factor for the NGS Market.

Inquiry Before Buying

By Application - Segment Analysis

The Diagnostics/Infectious Diseases segment displayed the largest share of the overall NGS market in 2018, and it is forecast to grow the fastest, at a CAGR of 9.32% during the period under consideration. The application of NGS technology in Diagnostics/Infectious Diseases is due to the growing cancer incidence and increased prevalence of genetic disorders in children. NGS technology helps to obtain better conclusions in medical diagnostic procedures.

Geography - Segment Analysis

In 2018, the North America region occupied 54% of the global Next Generation Sequencing market in terms of revenue. North America Next Generation Sequencing market is mainly attributed to the increasing technological developments in the countries, which has allowed growth in medical technology. The clinical use of this technology plays a significant part in shaping the healthcare industry and provides much precise, efficient, and safer alternatives to disease management which is driving the market as incidence. However, the Asia-pacific region is estimated to record the fastest growth rate during the forecast period.

Schedule a Call

Drivers – Next Generation Sequencing Market

High Investments In The Sector 

The new investments in the field by various companies have spun-up the growth of the NGS Market. The main reason firms invest in the technology is due to its high accuracy rates and capability to accurately spot the infected organs. As investment increases, advancements in the field also tend to grow aiding the growth of the market. 

Rising Application of Next Generation Sequencing 

NGS is expected to have various applications in the healthcare and medical technology market. The growth and dominance of new generation sequencing technology has caused a shift in the framework of scientific research, opening the doors to a new era of oncology research and diagnostics, as well as requiring scientists with stronger molecular knowledge alongside computational skills to carryout complex researches. 

Challenges – Next Generation Sequencing Market

High setup costs for laboratories. 

Diagnostic laboratories would have to invest enormous sums for the procurement and setting up of the equipment, software and consumables required for NGS. This often discourages small scale laboratories to adopt the new technology and forces then to continue using the traditional methods of identifying diseases. 

Buy Now

Market Landscape

Strategic partnerships and acquisitions along with product development and service launches are the key strategies of the players in the Next Generation Sequencing market. Some Key players in the market include, PierianDx, Saphetor, Macrogen Inc, Illumina Inc, GATC Biotech AG, F. Hoffmann-La Roche Ltd, DNASTAR Inc., Agilent , Technologies, Thermo Fisher Scientific Inc., Qiagen, PerkinElmer Inc and others. 

Next Generation Sequencing Market Research Scope: 

The base year of the study is 2018, with forecast done up to 2025. The study presents a thorough analysis of the competitive landscape, taking into account the market shares of the leading companies. These provide the key market participants with the necessary business intelligence and help them understand the future of the Next Generation Sequencing market. The assessment includes the forecast, an overview of the competitive structure, the market shares of the competitors, as well as the market trends, market demands, market drivers, market challenges, and product analysis. The market drivers and restraints have been assessed to fathom their impact over the forecast period. This report further identifies the key opportunities for growth while also detailing the key challenges and possible threats. The key areas of focus include the Sequence Type, Product Type, End User, Application & Geography.  

[mrfr-blogs]

Understanding the Share Dynamics in Next Generation Sequencing Market

Market Overview –

The next-generation sequencing (NGS) market focuses on providing advanced genomic analysis technologies that enable researchers to sequence and analyze DNA and RNA with unprecedented speed, accuracy, and throughput. NGS technologies have revolutionized genomic research, offering insights into genetic variations, gene expression patterns, and disease mechanisms.

The Next Generation Sequencing (NGS) Market is thriving with the widespread adoption of NGS DNA sequencing technologies. These advanced methods enable rapid and high-throughput sequencing of DNA, driving research and clinical applications. The market offers a range of platforms and services catering to diverse needs, from genomic analysis to personalized medicine, fueling its continuous growth and innovation.

Market growth is driven by several factors, including the increasing adoption of NGS in research and clinical diagnostics, growing demand for personalized medicine, and declining sequencing costs. As NGS becomes more accessible and affordable, there is a growing demand for sequencing services and platforms to support a wide range of applications, from basic research to clinical diagnostics.

Technological advancements and innovations in NGS platforms and bioinformatics tools are shaping the market, offering higher sequencing throughput, improved accuracy, and reduced turnaround times for genomic analysis. From sequencing instruments and reagents to data analysis software and cloud-based solutions, these advancements enhance researchers' ability to generate and interpret large-scale genomic data more efficiently.

Moreover, the expanding applications of NGS in areas such as cancer genomics, infectious disease surveillance, and prenatal screening are driving market growth, as researchers and healthcare providers seek to harness the power of genomics to improve patient care and outcomes. Additionally, the COVID-19 pandemic has accelerated the adoption of NGS technologies for viral genome sequencing and surveillance, highlighting the importance of genomics in understanding and controlling infectious diseases.

However, challenges such as data management, standardization, and regulatory compliance pose obstacles to market growth. Addressing these challenges requires collaboration between NGS technology providers, researchers, regulatory agencies, and healthcare stakeholders to develop standardized protocols, ensure data security, and establish quality assurance measures.

The Next Generation Sequencing Market Size was evaluated at USD 9.46 billion in 2021 and is expected to expand from USD 11.23 billion in 2022 to USD 44.24 billion by 2030, representing a compound yearly growth rate (CAGR) of 18.70% during the forecast period (2022- 2030).

Segmentation –

The global Next Generation Sequencing Market has been segmented based Technology, Workflow and end user.

The next generation sequencing market segmentation, based on technology, includes whole exome sequencing targeted sequencing and resequencing, and whole genome sequencing. Furthermore, targeted sequencing and resequencing bifurcated into DNA-based targeted sequencing & resequencing and RNA-based targeted sequencing & resequencing. The whole exome sequencing segment held the majority share in 2021 contribution to around ~40-42% in respect to the next generation revenue. This is owing to the technological advancements that allow for the rapid sequencing of large amounts of DNA.

The next generation sequencing market segmentation, based on workflow, includes pre-sequencing, sequencing, and data analysis. Furthermore, pre-sequencing has been segmented into NGS library preparation kits, NGS semi-automated library preparation kits, NGS automated library preparation kits, and clonal amplification moreover, data analysis further segmented by type into NGS primary data analysis, NGS secondary data analysis, and NGS tertiary data analysis. The pre-sequencing dominated the market in 2021 and is projected to be the faster-growing segment during the forecast period, 2022-2030. The sequencing is a critical step of the workflow and is a capital-intensive procedure that, in turn, accounts for a higher revenue generation. The last step in the next generation sequencing workflow is processing, analysis, and interpretation of the sequencing data generated.

Based on end user, the Next Generation Sequencing Market has been segmented into hospitals & clinics, diagnostic laboratories, pharmaceutical and biotechnology companies, and academic and research institutes. The diagnostic laboratories segment dominated the market in 2021, while academic & research institutes is projected to be the fastest-growing segment during the forecast period. There are two types of NGS tests for clinical diagnosis, namely, laboratory-developed tests (LDTs) and in-vitro diagnostics (IVDs). Adopting LDTs for routine clinical diagnostics requires ease of use for laboratories and quick turnaround to ensure timely decision-making by clinicians. Both IVDs and LDT are easily reproducible, attainable, reliable, and cost-effective results in the adoption of NGS technology.

Regional Analysis –

The next-generation sequencing (NGS) market displays distinct regional dynamics shaped by factors such as research funding, technological advancements, and regulatory frameworks. North America leads the market, driven by a robust biotechnology sector, extensive research activities, and supportive government initiatives.

The United States accounts for a significant share of NGS adoption, with academic institutions and biotech companies driving innovation. Europe follows closely behind, with countries like the UK, Germany, and France investing in genomic research and personalized medicine initiatives. In the Asia Pacific region, increasing investments in healthcare infrastructure and rising demand for precision medicine contribute to market growth, particularly in countries like China and Japan. Latin America and the Middle East & Africa regions also show potential for market expansion, albeit with challenges related to funding and infrastructure. Overall, the regional analysis underscores the importance of collaboration between industry stakeholders and policymakers to realize the full potential of NGS technologies in diverse healthcare settings.

Key Players –

Next-generation sequencing major players are Becton Eurofins Scientific based in the US, Illumina, Inc. from the US, Genome Life Sciences headquartered in India, GenScript based in the US, Thermo Fisher Scientific, Inc. also from the US, Qiagen headquartered in Germany, PerkinElmer, Inc. based in the US, F. Hoffmann-La Roche Ltd from Switzerland, Pacific Biosciences of California, Inc. headquartered in the US, Xcelris Genomics from India, along with other participants.

Related Reports –

Diabetic Ulcer Treatment

Medical Tourniquets

Forensic Swab

Ascites

For more information visit at MarketResearchFuture

[aimarketresearch]

Next Generation DNA Sequencing Market Size, Share, Trends, Demand, Future Growth, Challenges and Competitive Analysis

Data Bridge Market research has recently released expansive research titled Global Next Generation DNA Sequencing (NGS) Market  guarantees you will remain better informed than your competition.

Next Generation DNA Sequencing (NGS) Market report gives explanation about the different segments of the market analysis which is demanded by today’s businesses. Key players are taking actions such as developments, product launches, acquisitions, mergers, joint ventures and competitive analysis in the  industry. All the market aspects are estimated and analysed by a team of innovative, enthusiastic and motivated researchers and analysts so that nothing lefts uncovered in the report. Global Next Generation DNA Sequencing (NGS) Market research report, it becomes easy to figure out brand awareness and insight about the brand and product among potential customers.

Access Full 350 Pages PDF Report @

Data Bridge Market Research analyses that the next generation DNA sequencing (NGS) market was valued at USD 9.4 billion in 2021 and is expected to reach USD 40.42 billion by 2029, registering a CAGR of 20% during the forecast period of 2022 to 2029. The market report curated by the Data Bridge Market Research team includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.

Core Objective of Next Generation DNA Sequencing (NGS) Market:

Every firm in the Next Generation DNA Sequencing (NGS) Market has objectives but this market research report focus on the crucial objectives, so you can analysis about competition, future market, new products, and informative data that can raise your sales volume exponentially.

Size of the Next Generation DNA Sequencing (NGS) Market and growth rate factors.

Important changes in the future Next Generation DNA Sequencing (NGS) Market.

Top worldwide competitors of the Market.

Scope and product outlook of Next Generation DNA Sequencing (NGS) Market.

Developing regions with potential growth in the future.

Tough Challenges and risk faced in Market.

Global Next Generation DNA Sequencing (NGS) top manufacturers profile and sales statistics.

Key takeaways from the Next Generation DNA Sequencing (NGS) Market report:

Detailed considerate of Next Generation DNA Sequencing (NGS) Market-particular drivers, Trends, constraints, Restraints, Opportunities and major micro markets.

Comprehensive valuation of all prospects and threat in the

In depth study of industry strategies for growth of the Next Generation DNA Sequencing (NGS) Market-leading players.

Next Generation DNA Sequencing (NGS) Market latest innovations and major procedures.

Favorable dip inside Vigorous high-tech and market latest trends remarkable the Market.

Conclusive study about the growth conspiracy of Next Generation DNA Sequencing (NGS) Market for forthcoming years.

Frequently Asked Questions

What is the Future Market Value for Next Generation DNA Sequencing (NGS) Market?

What is the Growth Rate of the Next Generation DNA Sequencing (NGS) Market?

What are the Major Companies Operating in the Next Generation DNA Sequencing (NGS) Market?

Which Countries Data is covered in the Next Generation DNA Sequencing (NGS) Market?

What are the Main Data Pointers Covered in Next Generation DNA Sequencing (NGS) Market Report?

Some of the major players operating in the next generation DNA sequencing (NGS) market are:

Illumina, Inc. (US)

Thermo Fisher Scientific Inc. (US)

PerkinElmer, Inc. (US)

BGI Group (China)

Agilent Technologies, Inc. (US)

Eurofins Scientific (Luxembourg)

PacBio (US)

Oxford Nanopore Technologies plc (UK)

QIAGEN (Netherlands)

F. Hoffmann-La Roche Ltd. (Switzerland)

GENEWIZ Inc. (US)

Psomagen (South Korea)

10x Genomics (US)

Takara Bio Inc (Japan)

Bio-Rad Laboratories, Inc. (US)

Zymo Research Corporation (US)

Tecan Trading AG (Switzerland)

Hamilton Company (US)

Beckman Coulter, Inc. (US)

BD (US)

Lucigen Corporation (US)

Novogene Co., Ltd. (China)

Browse Trending Reports:

Nursing And Residential Care Market

Plastic Surgery Devices Market

Surgical Incision Closure Market

Respiratory Polygraphs Market

Biomedical Refrigerators And Freezers Market

About Data Bridge Market Research:

Data Bridge set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge endeavors to provide appropriate solutions to the complex business challenges and initiates an effortless decision-making process.

Contact Us:

Data Bridge Market Research

US: +1 888 387 2818

UK: +44 208 089 1725

Hong Kong: +852 8192 7475

Email: corporatesales@databridgemarketresearch.com

[roseaa11]

Technological advancements in the clinical next-generation sequencing (NSG) testing coupled with rising research and development proficiencies are fostering the market growth. Data Bridge Market Research analyses that the clinical next-generation sequencing (NSG) testing market will exhibit a CAGR of around 27.25% for the forecast period of 2021-2028.

[neha24blog]

U.S. Clinical Oncology Next Generation Sequencing Market Size Is Anticipated To Reach USD 1.53 Billion By 2024: Grand View Research Inc.

San Francisco, 27 April 2023: The Report U.S. Clinical Oncology Next Generation Sequencing Market Size, Share & Trends Analysis Report By Technology (Whole Genome Sequencing, Whole Exon Sequencing, Targeted Sequencing & Resequencing), By Workflow, By End Use, Regions, And Segment Forecasts 2018 To 2024 The U.S. clinical oncology next generation sequencing market is anticipated to reach USD 1.53…

[tbrcresearchreport]

The Business Research Company offers clinical oncology next generation sequencing market research report 2023 with industry size, share, segments and market growth

[stingslikeabee]

meet the mun

1. what made you pick up the current muse(s) you have?

I always credit Melissa to a combo of three particular things: a) my personal interest and passion for the Japanese nightlife scene and its uniqueness; b) the movie 'Sucker Punch' (and particularly the character of Vera Gorski); and c) a post that once made the rounds when I first joined the FFVII rpc that wondered if the Turks didn't visit Wall Market for the chili fries or because the girls happened to have the best intel.

And then it was like something clicked inside - I sudden had this 'vision' and Melissa was born after some crafting as a brothel madame who had strong mama bear/caring and nurturing vibes and who had set herself in opposition to Corneo. The two alternatives in terms of earning people's loyalty (fear/love), a cold war of sorts, a lot of fun and layered dynamics to play with from a Wall Market perspective (such as trading intel, working as an informant, etc) and tying in to the game main events.

I always preferred to pick 'minor' muses or to craft characters that fill in spaces and make a world livelier - Melissa just felt right. I guess she works nicely because no one ever thought it was absurd to have Corneo as a nemesis - even with Remake revamping the HBI and making it something else, I decided to stick to my OG view and I was incredibly well-accepted! :)

2. is there anything you don't like to write?

I am very plot driven - and therefore threads that are just winging something and with no ulterior purpose just bore me and I lose muse fast. I like threads to be like book chapters, with an objective in mind - once that's done, I prefer wrapping it up and starting a new one. Smaller things I deal with in asks (although there is nothing preventing me from turning an ask into a thread when it sparks the good muse food).

So I tend to have a basic, over-arching plot line to follow and I enjoy discussing it offline with my partners so we can ask each other what we are thinking in terms of next steps, if a certain event would be interesting, etc. Believe me, this doesn't take away the surprise - I have been hit by unexpected feelings so many times, I love it.

In addition to that, I struggle with fighting/action sequences (I am just super bad at it), overly descriptive things (a room, someone's clothes, a landscape). It just feels like everything I have ever studied about English goes out of the window and my writing turns super dull, I hate it.

3. is there anything you really enjoy writing?

Emotional stuff - of any kind. I have found out that my preferred writing method is one that mixes a lot of thoughts, emotions and bits of lore together, so although a given reply may not give much in terms of objective actions, it will make room for further emotional or introspective discussions to happen. Characters working out their own feelings and perceptions in relation to certain things is a favorite of mine and my replies are frequently novella-like because Melissa thinks (and feels) so damn much.

I also do like setting the scene (as in giving context for a particular interaction) in starters or asks and expanding on lore. Worldbuilding is another favorite of mine and I often make extensive research into stuff that is only going to be briefly mentioned in a thread. Other than that, I'm also into sharing/including NPCs to make the flow of a thread feel more like a book and crafting these small cameos is super fun.

Oh - I do enjoy writing the usual shippy things (including those on the platonic side of things), particularly with Melissa who has such a strong preference for these themes when compared to other muses. However, without plotting (and since she's an OC), it all feels very soulless if I don't know how to get there in a way that makes sense or seems to be aligned with every character involved.

4. how do you come up with headcanons?

I get inspired by different types of media and a lot of real-life references. For general lore/worldbuilding, I tend to leverage from historical or current events whenever possible, all the while trying to tie these things with the existing canon; for muse-specific verses, anything can spark an idea: a quote in a movie, a song, a certain TV show.

5. do you write in silence or do you play music?

I always have music on - it tends to change depending on the specific verse or muse, but I generally have key songs to fall to while writing.

6. do you plan your replies or wing them?

I plan them as a rule (including asks and memes) - even if it's mostly in my brain and as a general line that I want to follow so I can go from A to B within a few paragraphs. It doesn't always work, though - sometimes I rework the entire idea, or get hijacked by the muse and directed to something else instead.

7. do you enjoy shipping?

Yes - I adore it, and building connections and creating ships is something I really like to do, from discussing it to dropping aesthetic posts to a customized tag. For Melissa in particular, they play a large and significant role as she is someone very much transformed and shaped by love and attachment to people, so my ships for her invariably become a part of much larger and complex verses.

This also goes for platonic dynamics - I like the concept of ships because they allow me to visualize a setting/plot much better and build around it with so many little additions that it feels alive and organic. I start creating timelines and events and it is just so satisfying to see it all coming together.

One thing I have learned with time is that, despite enjoying shipping, I like to be able to talk/connect to the other mun offline (talking about it and plotting is fun!) but also I try to be selective to the point of exclusivity. Because I am so plot-driven, I end up building so much around one variant/portrayal of a given character that I just become partial to it and blind to others - and because I don't want to project my dynamics onto duplicates, I'm multi-single-ship as a result (as in multiple ships, but just a single one per each muse - although exceptions sometimes apply).

8. what's your alias/name?

Mari, because that's how everyone calls me anywhere, anytime. I actually get confused/bothered if my full name is used because it sounds more serious and I just think it's either a stranger calling me or a boss/my mother being angry, haha.

9. age?

Old enough to remember the hype re. having a Blockbuster card around here; these where the premium video rental shops, haha (and nope, I never had one, I only wished I had).

10. birthday?

A late winter/early spring child! As a kid I thought I was born in spring and loved it, but then I realized spring is just later in September and that I was actually a winter kid by a few days, haha. But growing up, winter (winter as I know it, mind you) became my favorite season, so it was all good!

11. favorite color(s)?

Used to be black, silver and blue but these days I'm super fond of turquoise and shades of green? I seemingly cannot settle on a single one forever.

12. favorite song(s)?

I am contractually required to always reply with 'GLAY' and 'Yuuwaku' haha (this song is so damn important in my life). Here's an awesome video to introduce you to my favorite band.

13. last movie you watched?

'The Girl with the Dragon Tattoo' - one of my top 10 favorite movies, one of my top 5 movie openings, one of my top 3 Fincher movies.

14. last show you watched?

I just finished (re)watching 'Nana', only this time I made it to the last episode. I forgot how emotional this show made me feel and how epic the soundtrack is.

15. last song you listened to?

'Raise Your Glass' by P!nk, a courtesy of my spotify shuffling things haha.

16. favorite food?

I never know what to say here, there is just SO MUCH I love? I think pasta generally ranks very high, followed by pastel and pão de queijo. On the sweet side, I am obsessed with coconut and paçoca.

17. favorite season?

I might have spoiled it here, but it's winter - again, my winter. Brazilian winter. Tropical winter. The winter I have experienced in the Netherlands was depressing, dark and horrible where my nose bled, my skin cracked, I got shocked every time I touched anything metallic and I was just miserable; I love blue skies with sunshine and something below 20 degrees outside.

18. do you have a tumblr best friend?

I do! I mean, I could just say that I have a bunch of really awesome mutuals and I wouldn't be lying; or that I am closer to some than to others, and that would also be true. But it's no secret that @dojimakaichou is just on another level because Dawn and I talk every day to the point I feel weird if we don't; we don't just talk about roleplay, we talk about everything, we have weekly movie dates, we send each other gifts, we record videos for our families and we spent 10 days together last year with plans for more annual encounters. :) She's my bestie (and not just a 'tumblr' bestie) and honestly I only wish we lived closer but we make do!

tagged by: @bitterarcs cursed me (and I loved it!) tagging: anyone who wants to - this has gone around for some time now so I'm pretty sure I'd be tagging people again~

[digitalivan]

How To Get More 5-Star Reviews & Amplify Your School Brand

Why Your School Needs Reviews Almost Everyone Reads Reviews 93% of U.S. consumers check online reviews so you can be sure that whenever someone is looking at a prospective new school, they're checking online to see if the school has reviews and if the sentiment is a positive one overall. FYI, not having any reviews isn't a good sign either. Reviews For Schools Are Trusted 72% of consumers trust online reviews as much as recommendations from friends and family. When it comes to school reviews, that number goes even higher. Reviews For Schools Are Influential 4 out of 5 consumers have reversed a purchase decision based on negative online reviews. Schools especially suffer when hit with negative reviews. Good School Reviews Are Under-Represented Unhappy customers tell an average of 24 people about their experience. Happy ones tell 15 people (usually after being prompted). Unsolicited reviews are typically negative so it makes sense for you to be proactive building your school's online reputation. Good Reviews Are Waiting to Happen 90% of typical U.S. consumers read online reviews yet only 6% write them. They're just waiting for an easy way to do it! 6 Reasons Why Happy People Don't Write Reviews - "Writing reviews is too tedious" - "I forgot to write the review" - "I have no time" - "No one asked me" - "I didn’t even think about it" - "I don’t know where to write the review" How to Convert More Happy Customers Into Reviewers STEP 1: Ask them to write a review STEP 2: Make the process easy STEP 3: Follow up with them in a convenient way The Reputation Solution: A "Review Funnel" How a Review Funnel Works - Ask and remind customers to share their experience online - Drive customers to a destination designed to convert them into reviewers - Guide each reviewer through selecting the best review site and completing a review Use Multiple Channels To Drive Parents & Students Into The Funnel Email Drip Campaigns Automatically email your parent with a drip sequence to encourage reviews! Website Widgets Put a review widget on your school's homepage, blog, or parent resource pages to encourage reviews. Printed "Invites" & Takeaways Give parents printed take-aways to encourage reviews. Convert Parents To Reviewers STEP 1: Ask For The Review With a easy-to-use clean landing page, we ask a for a review. Here, we pre-qualify the review to make sure it will be positive! STEP 2: Review Site Options Next, we present options on where we want the parent to leave a review. STEP 3: Review Complete The parent selects a website and leaves their review. Identify Unhappy Parents Before They Write A Review Happy parents are presented with review site options: Unhappy parents are taken to a private form where you can handle the complain privately via email: Monitor & Respond To Reviews & Promote Your Positive Reviews Awesome Reporting To Track Progress Unbeatable Features Review Acquisition - Collect school reviews with a customizable landing page - Custom website widget - Email footer widget - Mobile-friendly experience - Generates reviews on major review sites - Industry-specific sites - Collect reviews on site Review Funnels - Automated email funnels - SMS messaging - Printed review invites for offline integration Review Monitoring - Sends alerts when new reviews are published - Alerts include review info and link for response - Comprehensively monitors all reviews - Monitors all review sites - Includes major, minor, and industry-specific sites Review Marketing - Auto-share positive reviews to social media - Auto-publish reviews to your website - Embed rating with rich-snippet markup - Easy embed code - Includes aggregate reviews - Custom control over review publishing Click The Button Below To Start Getting Your 4 and 5-Star Reviews TODAY! How Many Locations? 1-3 schools : $400.00 USD - monthly 4-6 schools : $550.00 USD - monthly 7-10 schools : $750.00 USD - monthly               Read the full article

[trendingreportz]

Clinical Oncology Next Generation Sequencing Market - Forecast(2024 - 2030)

Clinical Oncology Next Generation Sequencing Market Overview

Clinical Oncology Next Generation Sequencing Market size was valued at $1.4 billion in 2020 and projected to grow at a CAGR of 13.6% during the forecast period 2021-2026. Next-generation sequencing is a technique that helps to simultaneously perform multiple reactions from which it is possible to sequence DNA or RNA. Biological sciences have been revolutionized by massively parallel sequencing technologies i.e. next-generation sequencing (NGS). Targeted sequencing and re-sequencing provides advantages such as high throughput and lower cost per sample of the process thereby enhancing its application Companion Diagnostics. It is a method of assessing the nucleotide sequence in a DNA section and is used for oncology research and enables researchers to carry out a wide range of applications and study biological systems with their ultra-high throughput, scalability, and speed at a level never before possible. In addition, sequencing of the next generation helps in the evaluation of several genes in a single assay, thus reducing the need to order numerous tests to evaluate the underlying mutation thereby driving the Clinical Oncology Next Generation Sequencing Market. In tumour science, a high implementation rate in whole-genome sequencing (WGS) has been seen in recent years driving the Clinical Oncology Next Generation Sequencing Market Industry. The emergence of next-generation sequencing clinical applications in precision oncology has accelerated key company’s efforts to create new platforms that can be used for genomic assays. In February 2021, for instance, Congenica partnered with Gabriel Precision Oncology Ltd. to create an automatic software interface for clinical oncology interpretation using biotechnology. In routine clinical practice, this product will promote NGS-based molecular diagnostics of tumours. 

Report Coverage

The report: “Clinical Oncology Next Generation Sequencing Market Forecast (2021-2026)”, by Industry ARC, covers an in-depth analysis of the following segments of the Clinical Oncology Next Generation Sequencing Market.

By Technology Type: Whole Genome Sequencing, Whole Exome Sequencing and Targeted Sequencing & Resequencing Centrifuges.

By Application: Screening - Sporadic Cancer and Inherited Cancer, Companion Diagnostics and Other Diagnostics.

By Workflow: NGS Pre-Sequencing, NGS Sequencing and NGS Data Analysis.

By End Use: Hospitals/Clinics, Laboratories and Research Labs.

By Geography: North America (U.S, Canada and Mexico), Europe (Germany, UK, France, Italy, Spain, Russia and Rest of Europe), Asia Pacific (China, Japan India, South Korea, Australia & New Zealand, and Rest of Asia Pacific), South America (Brazil, Argentina and Rest of South America) and RoW (Middle East and Africa).

Request Sample

Key Takeaways

The increasing need for successful treatment of various cancer types and scientific developments in immunology, molecular biology and genetics are likely to contribute to the growth of the Clinical Oncology Next Generation Sequencing industry.

Geographically, North America Clinical Oncology Next Generation Sequencing Market held the largest revenue share of 36% in 2020 owing to an increased emphasis on cancer treatment by government agencies, a rise in healthcare spending and the presence of sufficient resources in the healthcare industry in this region.

The growth of the market is driven by rising research and development activities using NGS technologies, growing NGS applications in clinical diagnosis and discovery applications that demand NGS technology.

Detailed analysis on the Strength, Weakness and Opportunities of the prominent players operating in the market is provided in the Clinical Oncology Next Generation Sequencing Market.

Clinical Oncology Next Generation Sequencing Market Segment Analysis - By Technology Type

Based on Technology Type, Clinical Oncology Next Generation Sequencing Market is segmented into Whole Genome Sequencing, Whole Exome Sequencing and Targeted Sequencing & Resequencing Centrifuges. Targeted Sequencing & Resequencing Centrifuges accounted for the largest revenue market share in 2020 help reduce the expense, time, and volume of data analysed during tumour sample sequencing which is anticipated to favourably impact the segment growth. Targeted sequencing uses deep sequencing within an area of interest to identify recognized and novel variants. Illumina's 523-gene panel contains all the probable genes that have the ability to cause malignant tumours to develop. Medical laboratories have introduced the product to diagnose patients suffering from acute myeloid leukaemia. In addition, the efficacy of targeted panels for the identification of malignant tumors improves their clinical usefulness. In 64% of cancer cases, NGS panels are clinically beneficial, according to a report reported in JCO Precision Oncology, 2020 driving the Clinical Oncology Next Generation Sequencing Industry. Whole Genome Sequencing segment is anticipated to grow with the fastest CAGR of 8.3% in the forecast period 2021-2026 owing to the usefulness of this technology to discern and compare normal tissues from tumour tissues, segment growth. Moreover, whole-genome sequencing of cancer patients helps to identify therapies for existing mutations and also helps to target mutations ahead of time. It also helps analyse the prognosis of cancer and establish a treatment regimen depending on the genes affected aiding to the Clinical Oncology Next Generation Sequencing Market growth.

Inquiry Before Buying

Clinical Oncology Next Generation Sequencing Market Segment Analysis - By Application

Based on Application, Clinical Oncology Next Generation Sequencing Market is segmented into Screening - Sporadic Cancer and Inherited Cancer, Companion Diagnostics and Other Diagnostics. Screening accounted for the largest revenue market share in 2020. The most effective way to identify genetic alterations that can be targeted for clinical benefit in cancer patients is currently considered to be NGS-based testing. This technology enables clinicians to analyse several alterations of genes simultaneously. Moreover, as opposed to other pathology methods, technology needs less tumor tissues. An increase in the number of cancer sequencing projects is also increasing the growth of the segment. For instance, 38 different types of cancer were analysed by the Pan-Cancer Analysis of Whole Genomes (PCAWG) Consortium by sequencing more than 2,600 tumour samples aiding to the market's growth. Companion Diagnostics segment is anticipated to grow with the fastest CAGR of 9.1% during the forecast period 2021-2026. Efforts taken by key market participants to develop advanced computational tools propel the segment growth. For instance, in January 2021, scientists from the MD Anderson Cancer Center created CopyKAT, a new computational tool to distinguish between normal as well as cancer cells in a tumour thus enhancing the Companion Diagnostics segment demand.

Clinical Oncology Next Generation Sequencing Market Segment Analysis - By Geography

Based on Geography, North America Clinical Oncology Next Generation Sequencing Market accounted for the 36% revenue share in 2020. This rise is accounted for by substantial efforts made by regulatory bodies to boost cancer screening detection in the U.S. For instance, the U.S.-initiated Cancer Genome Atlas programme, Next-generation sequencing has been conducted by the National Cancer Institute (NCI) of more than 20,000 primary cancer samples from 33 different cancer types. A consortium of 12 cancer centres, including Johns Hopkins University, Dana-Farber Cancer Institute, and others throughout the United States, is the NCI's Cancer Aim Discovery and Growth Network enhancing the Clinical Oncology Next Generation Sequencing Market. In January 2020, in the United States, the Intelligence Advanced Research Projects Activity provided $23 million to the Broad Institute and Harvard University, and DNA Script. In addition, the emergence of a range of laboratories, academic institutions and hospitals that provide early cancer detection and treatment services based on NGS is owing to the growth of the regional sector. For instance, EasyDNA Canada, a Toronto-based DNA Biotechnology testing company, provides Cancer Predisposition Panel tests that use NGS technology to recognise mutations in a total of 98 genes associated with 25 inherited cancers. The test helps to recognise people who at a later stage of their lives are at a high risk of developing cancer drive the regional growth. Asia-Pacific is predicted to be the fastest-growing region during the forecast period 2021- 2026 owing to the increasing automation in the pre-sequencing protocols in this particular region thereby aiding to regional growth.

Schedule a Call

Clinical Oncology Next Generation Sequencing Market Drivers

Increasing Prevalence of Cancer:

Cancer is the second leading cause of death worldwide, according to the WHO, and was responsible for an estimated 9.6 million fatalities in 2018. Need for cancer therapies is rising with the increasing number of cancer cases and deaths caused by cancer. Thus government of various economies focus on drug development, targeted sequencing for the reduction of cancer cases have also increased. Rising biomedical research using next-generation clinical oncology sequencing is estimated to create a favourable environment in the near future for the growth of the next-generation clinical oncology sequencing industry. With substantial advances in genetic sequencing and biomedical science, much research into monoclonal antibodies is now focused on discovering new development targets and optimizing their effectiveness for clinical practice, demonstrating a significant effect on the need for the Clinical Oncology Next Generation Sequencing Market.

Decreasing Sequencing Costs Are Highly Likely To Lead To Market Growth:

In clinical oncology, research and academic institutions are generally interested in the characteristic features of next-generation targeted sequencing technology. The next-generation sequencing techniques in clinical oncology give a high percentage of reads and cost-effectiveness per read. The arrival of low-cost sequencing platforms on the market has made this possible. This increases the overall growth of the next-generation sequencing market for clinical oncology. Several industry players, such as Roche and Illumina, have launched sequencing techniques that have reduced the cost of next-generation sequencing for clinical oncology. Government support for life science research is also estimated to result in the availability of funding for the undertaking of different next-generation sequencing projects in clinical oncology, as well as for the jobs of the staff needed which further act as a driving factor for the growth of the Clinical Oncology Industry.

Clinical Oncology Next Generation Sequencing Market Challenges

Major Regulatory Concerns & Lack Skilled Professionals:

Regulatory concerns regarding usage of Clinical Oncology Next Generation Sequencing Analysis and growing stringent government policy and regulation towards the quantity of service being used in application is restraining growth of the market. Market restrain is also owing to the difficulty in the management of large data and complications, associated with Big Data management. In addition, some of the ethical issues associated with whole-genome sequencing, coupled with the lack of awareness among people are constraining the growth of the market. In addition, the lack of skilled professionals with the sequencing that could be serious for diagnosis purpose set to restrain the market growth. It gets difficult when in an emergency situation, the queue of patients have to wait for experts in the required field negatively impacting the growth.

Buy Now

Clinical Oncology Next Generation Sequencing Industry Outlook:

Product launches, mergers and acquisitions, joint ventures and geographical expansions are key strategies adopted by players in the Clinical Oncology Next Generation Sequencing Market. Clinical Oncology Next Generation Sequencing Market top 10 companies are Illumina, Inc., Qiagen N.V., Pacific Biosciences of California, Inc., Takara Bio, Inc., Creative Biolabs, Mogene LC, F. Hoffmann-La Roche Ltd, Oxford Nanopore Technologies, Agilent Technologies and Thermo Fisher Scientific Inc.

Acquisitions/Product Launches:

In January 2021, 4baseCare, a start-up in precision oncology, partnered with the Advanced Centre for Cancer Treatment, Study and Education (ACTREC), India, to develop ClinOme, an AI-driven platform for clinical interpretation

In May 2020, Illumina, Inc., has partnered with Burning Rock Biotech Limited, a cancer test provider based in China, to promote the standardisation and development within China of the selection of NGS-based cancer therapy. The company has also signed an agreement to develop and commercialise myChoice tumour testing in China with Myriad Genetics, Inc.

In March 2019, Oxford Nanopore Technologies launched a new paradigm of smaller, on-demand DNA or RNA sequencing tests with the potential to transform a variety of applications where rapid insights are needed at a low cost.

[datastring]

Brazil, Russia, and India are the new opportunity grounds for Xenografts market players

According to a recent research, Industry revenue for Xenografts is expected to rise to $5.6 billion by 2035 from $2.3 billion of 2024. U.S., Germany and China are the top 3 markets and combinely holds substantial demand share. The revenue growth of market players in these countries is expected to range between 6% and 8.6% annually for period 2025 to 2035.

Industry transition including shift towards personalized medicine and advancements in xenotransplantation, are transforming the supply chain of Xenografts market. In the realm of sequencing progress is rapidly growing; xenograft procedures are undergoing a notable shift towards personalized medicine tailored to individual cancer mutations of patients. A pivotal step in transforming cancer treatments for the betterment of all involved parties. This shift is exemplified by the integration of xenograft technology, in systems or organ on a chip crafting patient specific tumor models that enhance treatment precision and minimize the trial and error process often linked with conventional therapeutic approaches. The shift is having an effect on the pharmaceutical and biotechnology sectors as it boosts the need for xenograft usage, in drug advancement and personalized medicine studies.

Check detailed report here - https://datastringconsulting.com/industry-analysis/xenografts-market-research-report

Research Study addresses the market dynamics including opportunities, competition analysis, industry insights for Product Type (Human, Animal), Application (Oncology Research, Regenerative Medicine, Drug Discovery, Other Applications, Others) and Technology (Polymerase Chain Reaction, Next Generation Sequencing, Microarray).

Industry Leadership and Strategies

Companies such as Thermo Fisher Scientific Inc., PeproTech Inc., STEMCELL Technologies Inc., CREATIVE BIOARRAY, Xenopat, Crown Bioscience Inc., Charles River Laboratories, Hera Biolabs, Shanghai Biochip Co Ltd., GEMoaB GmbH, Biocytogen and Champions Oncology Inc. are well placed in the market. Below table summarize the strategies employed by these players within the eco-system.

Application Area

Leading Providers / Consumers

Provider Strategies

Cancer Research

Thermo Fisher Scientific

Innovation and strong investment in R&D for robust Xenograft models

Pharmacokinetics Research

Crown Bioscience

Collaborates with pharmaceutical companies and adopts advanced protocols for the development of Xenografts

Tissue Engineering

Merck KGaA

Leverages cutting-edge technologies and strategic partnerships to enhance capabilities in Xenograft applications

Evolving & Shifting Regional Markets

North America and Europe are the two most active and leading regions in the market. With different regional dynamics and industry challenges like ethical concerns and regulatory hurdles and limited success rate and rejection risks; market supply chain from raw material providers to end-users is expected to evolve & expand further, especially within emerging markets

The market in emerging countries is expected to expand substantially between 2025 and 2030, supported by market drivers such as increasing demand for personalized medicine, advancements in genetic engineering, and rising prevalence of cancer.

About DataString Consulting

DataString Consulting assist companies in strategy formulations & roadmap creation including TAM expansion, revenue diversification strategies and venturing into new markets; by offering in depth insights into developing trends and competitor landscapes as well as customer demographics. Our customized & direct strategies, filters industry noises into new opportunities; and reduces the effective connect time between products and its market niche.

DataString Consulting offers complete range of market research and business intelligence solutions for both B2C and B2B markets all under one roof. DataString’s leadership team has more than 30 years of combined experience in Market & business research and strategy advisory across the world. Our Industry experts and data aggregators continuously track & monitor high growth segments within more than 15 industries and 60 sub-industries.

https://datastringconsulting.com/downloadsample/xenografts-market-research-report

[adhk1234]

Bioinformatics Market: Company Profiles and Strategic Insights

The bioinformatics market is experiencing significant expansion, with its valuation standing at USD 11.45 billion in 2023 and an anticipated growth to USD 35.38 billion by 2032, reflecting a compound annual growth rate (CAGR) of 13.38% during the forecast period from 2024 to 2032.

Market Overview

Bioinformatics, the interdisciplinary field that combines biology, computer science, and information technology, has become indispensable in managing and analyzing vast amounts of biological data. Its applications span genomics, proteomics, metabolomics, and drug discovery, among others.

Get free sample report @ https://www.snsinsider.com/sample-request/1755

Regional Analysis

North America: Leading the market due to substantial investments in research and development, advanced healthcare infrastructure, and the presence of key industry players.

Europe: Experiencing significant growth driven by government initiatives supporting genomics research and personalized medicine.

Asia-Pacific: Projected to witness the fastest growth, attributed to increasing healthcare expenditures, rising awareness of bioinformatics applications, and expanding research activities in emerging economies.

Market Segmentation

The bioinformatics market is segmented based on product, application, and region:

By Product:

Bioinformatics Platforms

Bioinformatics Services

Biocontent Management

By Application:

Genomics

Molecular Phylogenetics

Metabolomics

Proteomics

Transcriptomics

Cheminformatics and Drug Designing

Others

Top Bioinformatics Companies

1. DNAnexus Inc.

DNAnexus Platform (cloud-based platform for data analysis, management, and sharing), DNAnexus Apollo (genomic data management and analysis software)

2. Seven Bridges Genomics

Seven Bridges Platform (cloud-based bioinformatics platform for data analysis and collaboration), Seven Bridges Genomics Software Suite (tools for NGS data analysis)

3. BGI Group

BGISEQ-500 (Next-generation sequencing platform), BGI Genomics Bioinformatics Platform (genetic data analysis and bioinformatics solutions)

4. Partek Inc.

Partek Genomics Suite (software for genomic data analysis), Partek Flow (cloud-based platform for genomics data analysis), Partek Pathway (biological pathway analysis)

5. Thermo Fisher Scientific

Thermo Fischer Ion Torrent (sequencing technology), Thermo Fisher GeneArt (synthetic biology tools), Thermo Fisher Bioinformatics Solutions (data analysis software)

6. Qiagen

Qiagen CLC Genomics Workbench (bioinformatics software for sequencing data analysis), Qiagen Ingenuity Pathway Analysis (IPA) (pathway analysis and bioinformatics solutions)

7. Agilent Technologies

Agilent Genomic Workbench (software for DNA and RNA analysis), SureSelect Target Enrichment System (NGS solution), Agilent Bioinformatics Software (data analysis for life sciences)

8. Illumina

BaseSpace Sequence Hub (cloud-based bioinformatics platform for sequencing data analysis), Illumina NextSeq (sequencing platform), Illumina DRAGEN Bio-IT Platform (AI-driven platform for genomic analysis)

9. PerkinElmer

PerkinElmer Bioinformatics Solutions (for sequencing, microarray, and NGS analysis), ChemDraw (molecular structure drawing software), ChemBioOffice (for bioinformatics data analysis)

10. Eurofins Scientific

Eurofins Genomics Bioinformatics Services (data analysis and genomic solutions), Eurofins GeneScan (DNA sequencing services)

11. Waters Corporation

Waters MassLynx Software (for bioinformatics analysis of proteomics data), Waters Empower Chromatography Software (data analysis in chromatography and proteomics)

12. DNASTAR

DNASTAR Lasergene (software for sequence analysis and bioinformatics), DNASTAR Genomics Suite (bioinformatics tools for NGS analysis)

13. NeoGenomics Laboratories

NeoGenomics Genomic Data Analysis Services (bioinformatics services for cancer genomics), NeoGenomics OncoPanel (NGS bioinformatics for cancer profiling)

14. GENEWIZ

GENEWIZ Bioinformatics Analysis Services (genomic data analysis services), GENEWIZ DNA Sequencing (NGS and Sanger sequencing services)

15. Fios Genomics

Fios Genomics Bioinformatics Services (NGS data analysis), Fios Genomics Gene Expression Analysis (for RNA-Seq analysis)

16. SOPHiA Genetics

SOPHiA DDM (Data-Driven Medicine Platform for NGS analysis), SOPHiA AI Platform (AI-driven genomic data analysis)

17. Source BioScience

Source BioScience Bioinformatics Services (sequencing and data analysis), Source BioScience NGS Services (bioinformatics support for NGS)

18. Biomax Informatics AG

Biomax Bioinformatics Software Suite (data mining and analysis tools for proteomics, genomics, and drug discovery), Biomax BioXM (bioinformatics platform for data integration and analysis)

Key Highlights

Advancements in next-generation sequencing (NGS) technologies are propelling the demand for bioinformatics tools to manage and interpret complex genomic data.

The integration of artificial intelligence (AI) and machine learning (ML) in bioinformatics is enhancing predictive analytics and personalized medicine approaches.

Growing investments in precision medicine and the increasing prevalence of chronic diseases are driving the adoption of bioinformatics in healthcare.

Future Outlook

The future of the bioinformatics market appears promising, with continuous technological innovations and expanding applications across various sectors. The integration of cloud computing and big data analytics is expected to further streamline data management and analysis processes. Additionally, collaborations between academic institutions, research organizations, and industry players are anticipated to foster the development of novel bioinformatics solutions, thereby accelerating advancements in genomics, personalized medicine, and other related fields.

Conclusion

As the bioinformatics landscape evolves, it presents numerous opportunities for stakeholders across healthcare, agriculture, environmental science, and other domains. Staying abreast of technological advancements and market dynamics will be crucial for organizations aiming to leverage bioinformatics to drive innovation and achieve competitive advantage.

Contact Us: Jagney Dave - Vice President of Client Engagement Phone: +1-315 636 4242 (US) | +44- 20 3290 5010 (UK)

Other Related Reports:

Pharmacy Benefit Management Market

Behavioral Health Software Market

Precision Medicine Software Market

[healthcaremarketanalysis]

Respiratory Diagnostics Market worth $9.02 billion by 2030

The report “Respiratory Diagnostics Market by Product & Services (Instrument & Devices), Test type (Mechanical, OSA, Imaging, Molecular Test), Disease (Tuberculosis, COPD, Lung Cancer ) and Diagnosis Type (Syndromic, Aetiological, Prognosis) — Global Forecast to 2030”, is expected to reach USD 9.02 billion by 2030 from USD 6.17 billion in 2024, at a CAGR of 6.5%, during the forecast period.

Browse 489 market data Tables and 71 Figures spread through 403 Pages and in-depth TOC on “Respiratory Diagnostics Market by Product & Services (Instrument & Devices), Test type (Mechanical, OSA, Imaging, Molecular Test), Disease (Tuberculosis, COPD, Lung Cancer ) and Diagnosis Type (Syndromic, Aetiological, Prognosis) — Global Forecast to 2030” View detailed Table of Content here — https://www.marketsandmarkets.com/Market-Reports/respiratory-diagnostics-market-163390459.html

Application of artificial intelligence and data analytics into respiratory diagnostics permits a more optimized usage of efforts in analyzing complex data, thereby allowing for earlier detection and personalized treatment plans. It has emerged with the global health emergency, particularly with the COVID-19 pandemic, underscoring the reality of respiratory diagnostics. It resulted in quick and appropriate diagnostics during the outbreak that gives rise to encouraging innovations and market growth. Government efforts towards prevention and management of respiratory diseases, along with enabling healthcare policies, higher funding, and support, will further facilitate the adoption of advanced diagnostic technology. Technological advancements in diagnostic methods, including imaging techniques, molecular diagnostics, and rapid methods, improve respiratory diagnosis accuracy and efficiency. Technological improvement always drives market growth through the provision of better diagnostic tools. More peculiar input in healthcare necessitates the recognition of both professionals and the general population on the importance of early detection and diagnosis of respiratory diseases. High costs incurred in most advanced imaging and molecular diagnostic respiratory tests have become barriers to accessibility and adoption thereby limiting market growth in resource-constrained regions.

“Based on products and services, instruments and devices segment accounted for the largest share in the maket in 2023.”

These point-of-care tests are taking health care into a number of different places which is expanding the markets for instruments and devices. Portable diagnostic devices, including hand-held spirometers, peak flow meters, and mobile imaging devices, can allow for immediate evaluation of lung function and conditions. Early appropriate treatment initiation improves patient outcomes due to possible point-of-care respiratory diagnosis improving diagnostic efficacy. Hence, this justifies a transition to a more personalized, timely care, of which respiratory diagnostic instruments are one element of the changing demands of health care. Innovations in the diagnostic device further fuel the trend by allowing for the most accurate, quickest, and least invasive diagnosis of pulmonary diseases.

“By test type, the molecular diagnostic test segment is expected to grow at the fastest CAGR in the market during the forecast period.”

The molecular diagnostic segment of tests is expected to register the highest growth rate during the forecast period in the respiratory diagnostic market. This trend is attributed to the growing demand for accurate and rapid diagnostics, particularly in the detection of respiratory infections such as COVID-19 and influenza as well as other viral diseases. Techniques such as PCR and next-generation sequencing are known to be included in molecular diagnostics with their high precision and enabling rapid and reliable results. Such growth in these diagnostic practices is brought about by an increase in infectious diseases and technological advances and by increasing awareness of healthcare. Personalized treatment can thus also be facilitated with molecular diagnostics, which add to its demand in clinical scenarios.

“By disease indication, asthma segment accounted for the largest share of the global respiratory diagnostics market.”

Personalized asthma management increasingly relies on complex and advanced tools of diagnosis, with regard to the individually focused patients. Such advanced diagnostics for asthma like molecular testing and biomarker analyses help providers to explore the various genetics and molecular bases behind a patient’s asthma. By understanding these convolutions, it becomes much easier to establish the most personalized and targeted strategies-they almost begin to be called “target medicine.” Hence, the segment specific to asthma in respiratory diagnostics is poised for healthy exposure to exponential growth, due to the improving trend toward the adoption of personalized medicine.

“By type of diagnosis, syndromic segment is expected to grow at the fastest rate in the global respiratory diagnostics market during the forecast period.”

Among the various type of diagnosis syndromic is expected to grow at a very fast rate in the global respiratory diagnostics market, as it is capable of rapidly identifying a broad range of organisms with a single diagnostic test. It allows the clinician to institute the most appropriate management in the least possible time, especially in an urgent care setting. The increase in incidence of respiratory infections, a growing demand for rapid diagnostic solutions, and advancements in multiplex PCR and next-generation sequencing technologies will boost the segment growth. In addition, the emerging trend of point-of-care testing and the greater need for cost-effective, efficient diagnostics in resource-poor environments further augment the segment’s rapid growth.

“By end users, hospitals and clinics end-user segment held the largest market share growing at the highest CAGR during the forecast period of the respiratory diagnostics market.”

With the increasing trend, hospitals and clinics are accepting respiratory diagnostics as a complete part of the routine care model. Seamless inclusion of respiratory diagnostics in hospitals and clinics affords convenience for patients to access diagnostic services, whether they come from seeking primary care or specialized services for a problem. Early detection of diseases, as well as the patient’s health in terms of being proactive, as measured by the repeated measures of respiratory health within a specific time frame, helps to determine timely intervention with an individualized treatment plan. Integrated diagnostic measures become part of the patient’s care pathway and support immediate intervention based on diagnosis. With hospitals and clinics becoming main sites for respiratory diagnosis in a typical care routine, the demand for such services is bound to expand and, therefore, is expected to be a driver for growth in the respiratory diagnostics market.

“By region, North America has accounted for the largest share in the market in 2023.”

North America accounted for the largest share in the respiratory diagnostics market in 2023. Awareness about timely diagnosis and proper management of diseases concerning the respiratory tract is one of the main factors driving the use of respiratory diagnostics products and services in North America. At the same time, increased public awareness generally influenced a behavioral change in the health-seeking activities of individuals making them more likely to seek respiratory health evaluations. As they recognize the potential detrimental effects of respiratory diseases on the well-being of their lives, individuals collectively prefer undergoing diagnostic tests for early identification and timely intervention. Thus, this increased use of respiratory diagnostics not only leads to improved outcomes for the patient via early identification and management of respiratory pathologies but is, in itself, a drive for the growth of the respiratory diagnostics market in North America.

Key Market Players

Prominent players in the respiratory diagnostics market are Koninklijke Philips N.V. (Netherlands), Becton, Dickinson and Company (US), Abbott Laboratories (US), Thermo Fisher Scientific Inc. (US), GE Healthcare Technologies Inc. (US), Bio-Rad Laboratories, Inc. (US), Blomerieux (France), Revvity, Inc. (US), Seegene Inc. (South Korea), Nihon Kohden Corporation (Japan), Vitalograph (UK), SDI Diagnostics (US), ResMed Inc. (US), Siemens Healthineers AG (Germany), Cosmed srl (Italy), Hologic, Inc. (US), Qiagen N.V. (Germany), MGC Diagnostics Corporation (US), Visby Medical, Inc (US), Briota Technologies Pvt Ltd (India), Bird HealthCare (Australia), Lowenstein Medical SE & Co. KG (Germany), Proaxsis (Ireland), NDD Medical Technologies (US), and Compumedics Limited (Australia).

Recent Developments of Respiratory Diagnostics Market -In September 2024, Becton, Dickinson and Company (US) acquired Edwards Lifesciences Corporation’s Critical Care product group. The product group is now renamed BD Advanced Patient Monitoring, unlocking new value opportunities and enhancing BD’s innovative connected care solutions portfolio. -In June 2024, bioMérieux (France) declared that the BIOFIRE SPOTFIRE Respiratory/Sore Throat (R/ST) Panel Mini has received the US FDA Special 510(k) approval and CLIA-waiver (Clinical Laboratory Improvement Amendments). This unique multiplex PCR test detects five of the most common viral & bacterial causes of respiratory or sore throat infections in about 15 minutes. -In January 2024, Wipro GE Healthcare, a Joint Venture (JV) between GE Precision Healthcare LLC (US) and Wipro Enterprises Limited (India), signed a MoU with the Indian Institute of Science (IISc) (India) to advance healthcare innovation, research, and technology development in India. -In August 2023, Bio-Rad Laboratories, Inc. (US) launched two products, PTC Tempo 48/48 and PTC Tempo 384, designed to support PCR applications in basic and translational research, process development, and quality control.

[snehalblog]

MENA Syringes & Cannula Market: Key Growth Drivers and Future Outlook - UnivDatos

According to a new report by UnivDatos Market Insights, The MENA Syringes & Cannula Market was valued at USD 1,505.79 million in the year 2023 and is expected to grow at a strong CAGR of around 7.29% during the forecast period. Owing to the aging population is more vulnerable to illnesses that require hospitalization and medical procedures that involve syringes and cannula. As per the United Nations Population Fund (UNFPA), in 2024, the United Arab Emirates is going through a demographic transition as the number of persons aged 60+ is expected to increase more than six-fold between 2020 - 2050 from about 311,000 (3.1% of the total population) to 2 million (19.7%). Adding to this, the increased rate of diabetes, cardiovascular diseases, and other chronic diseases led to other increased frequency of standard medical procedures. Furthermore, the use of devices like cannula for surgeries and treatments has increased as medical procedures have advanced.

Request To Download Sample of This Strategic Report - https://univdatos.com/reports/causal-ai-market?popup=report-enquiry&utm_source=LinkSJ&utm_medium=Snehal&utm_campaign=Snehal&utm_id=snehal

The report suggests that Syringes & Cannula resources in the MENA region had a significant impact on the Syringes & Cannula industry in the MENA region. Some of how this impact has been felt include:

· In April 2024: Medline announced it has entered into a definitive agreement to acquire Ecolab, Inc.'s global surgical solutions business, including the industry-leading Microtek product lines. Once closed, the acquisition will provide Medline with innovative sterile drape solutions for surgeons, patients, operating room equipment, and Ecolab’s fluid temperature management system.

· In May 2023, Pfizer and Thermo Fisher Scientific Inc. announced they have entered into a collaboration agreement to help increase local access to next-generation sequencing (NGS)-based testing for lung and breast cancer patients in more than 30 countries across Latin America, Africa, the Middle East and Asia where advanced genomic testing has previously been limited or unavailable.

· In February 2021, the Advanced Medical Technology Association (AdvaMed) inked a MoU, entering a formal relationship with MECOMED, MEA’s medical devices, imaging, and diagnostics trade association. The collaboration facilitated information sharing between both organizations and increased the ability to strengthen this market.

· In May 2021, Medovate, a medical device manufacturer in the U.K., announced a partnership in the Middle East. The Cambridge-based specialist has teamed up with Kuwait’s Omneya Medical Co. to distribute its SAFIRA (SAFer Injection for Regional Anesthesia) device in the Gulf country.

Apart from this, in recent years, UAE has significant growth in MENA, and North Africa has enhanced the growth of the Syringes & Cannula industry:

The UAE is expected to grow with a significant CAGR during the forecast period (2024-2032). The market of syringes and cannula in UAE is consequently driven by government initiatives to enhance healthcare and construct better healthcare facilities. The current government’s investment in health under Vision 2021 has emphasized quality health facilities that depend majorly on medical disposables for the overall safe course of medical practice. For instance, in October 2022, the Ministry of Industry and Advanced Technology (MoIAT) announced the signing of a pair of MoU worth Dh 260 million (USD 7 million) between major pharmaceutical companies and medical devices companies in the United Arab Emirates. The UAE has a well-developed healthcare sector featuring modern hospitals and clinics generating demand for superior medical consumables like syringes and cannula. In addition, the UAE is one of the prominent medical tourism destinations in the region, hosting patients from all corners of the world and adding to the demand for medical devices and supplies.

Ask for Report Customization - https://univdatos.com/reports/causal-ai-market?popup=report-enquiry&utm_source=LinkSJ&utm_medium=Snehal&utm_campaign=Snehal&utm_id=snehal

Conclusion

In conclusion, Syringes & Cannula market in the MENA region is anticipated to show considerable growth in the future due to strategic healthcare investments and increasing incidences of chronic diseases. It was found that technological factors are indeed crucial, of which the move towards safer and more efficient medical device is prominent. However, one of the major issues facing the market players is the operationalization of these diverse regulatory frameworks regarding renewable energy implementation within the different countries of the MENA region. Therefore, in the future, the focus must be on long-term development and marketing, investing in innovation and compliance to capture new opportunities and maintain the scale of competitiveness in this evolving and growing healthcare market.

[anujmrfr]

Precision Genomic Testing Market Size, Growth Outlook 2035

The global Precision Genomic Testing Market Size was estimated at 15.54 (USD Billion) in 2024. The Precision Genomic Testing Market Industry is expected to grow from 16.99 (USD Billion) in 2025 to 37.92 (USD Billion) till 2034, at a CAGR (growth rate) is expected to be around 9.33% during the forecast period (2025 - 2034).

Market Overview The Precision Genomic Testing Market is growing rapidly due to advancements in genomic sequencing, personalized medicine, and biomarker-driven therapies. Precision genomic testing enables early disease detection, targeted therapy selection, and risk assessment for genetic disorders. The increasing prevalence of cancer, rare genetic diseases, and chronic conditions has fueled demand for highly accurate and rapid genomic analysis. Moreover, the integration of artificial intelligence (AI) in genomic data interpretation is enhancing the efficiency of precision diagnostics.

Market Size and Share The global Precision Genomic Testing MarketSize was estimated at 15.54 (USD Billion) in 2024. The Precision Genomic Testing Market Industry is expected to grow from 16.99 (USD Billion) in 2025 to 37.92 (USD Billion) till 2034, at a CAGR (growth rate) is expected to be around 9.33% during the forecast period (2025 - 2034). North America holds the largest market share due to the presence of leading biotechnology firms, high investments in precision medicine, and widespread adoption of genomic testing in oncology. The Asia-Pacific region is projected to witness the highest growth, driven by rising government funding for genetic research, growing medical tourism, and increasing awareness of personalized treatments.

Market Drivers

Growing Adoption of Personalized Medicine: The demand for tailored treatment plans based on genetic profiling is increasing in oncology, cardiology, and neurology.

Advancements in Next-Generation Sequencing (NGS) Technologies: The development of rapid and cost-effective sequencing platforms is enhancing the accessibility of precision genomic testing.

Increasing Prevalence of Genetic Disorders and Cancer: The rise in hereditary diseases, rare genetic conditions, and tumor profiling needs is fueling market growth.

Integration of AI and Bioinformatics in Genomic Testing: AI-powered genomic analysis tools are improving the accuracy and speed of genetic variant detection.

Challenges and Restraints

High Cost of Genomic Testing: Advanced precision diagnostic tests can be expensive, limiting accessibility in lower-income regions.

Data Privacy and Ethical Concerns: The storage and sharing of genetic data raise ethical issues and require stringent regulatory compliance.

Complexity of Genomic Data Interpretation: Large-scale genomic datasets require sophisticated bioinformatics tools and expertise for accurate analysis.

Market Trends

Expansion of Liquid Biopsy-Based Genomic Testing: The shift toward non-invasive cancer diagnostics is gaining traction.

Development of CRISPR-Based Genomic Screening Tools: Advancing gene editing technologies are revolutionizing genetic disease research.

Increasing Use of Pharmacogenomic Testing: Optimizing drug selection and dosage based on genetic profiles is enhancing treatment outcomes.

Regional Analysis

North America: Dominates the market due to high adoption of precision medicine, strong R&D infrastructure, and favorable government initiatives.

Europe: Significant growth driven by biomarker-based drug development and expanding applications of genomic sequencing.

Asia-Pacific: Fastest-growing region with increasing investments in genomic research, personalized medicine, and biotechnology advancements.

Rest of the World: Moderate growth in Latin America and the Middle East due to increasing adoption of genetic testing technologies.

Segmental Analysis

By Technology:

Next-Generation Sequencing (NGS)

Microarray Technology

Polymerase Chain Reaction (PCR)

Fluorescence In Situ Hybridization (FISH)

By Application:

Oncology Genomic Testing

Cardiovascular Disease Risk Assessment

Rare Genetic Disorder Screening

Pharmacogenomic Testing

By End-User:

Hospitals & Diagnostic Laboratories

Biotechnology & Pharmaceutical Companies

Research Institutes

Key Market Players

Thermo Fisher Scientific

Guardant Health

GRAIL

  Roche

PerkinElmer

Exact Sciences

BristolMyers Squibb

Recent Developments

Launch of AI-Driven Genomic Interpretation Platforms: Enhancing efficiency in cancer genomics and disease risk assessment.

Strategic Collaborations Between Biotech Firms and Healthcare Providers: Expanding access to precision genomic testing.

Development of Rapid, Low-Cost Whole Genome Sequencing Technologies: Making personalized genomic analysis more affordable.

For more information, please visit us at marketresearchfuture.